Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Christophe Massard(Institut Gustave Roussy), Karim Fizazi(Université de Lille)

British Journal of Cancer

September 18, 2007

10.1038/sj.bjc.6603942

Cited by 46

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

|New England Journal of Medicine|2014|3k

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

|New England Journal of Medicine|2012|2.8k

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

|Journal of Clinical Oncology|2016|1.6k

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

|The Lancet Oncology|2012|1.4k

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

|The Lancet Oncology|2015|1.4k